Phase 1 ALS trial is first to test antisense treatment of neurodegenerative disease: No serious adverse effects reported
Wednesday, April 3, 2013 - 16:00
in Health & Medicine
The initial clinical trial of a novel approach to treating amyotrophic lateral sclerosis -- blocking production of a mutant protein that causes an inherited form of the progressive neurodegererative disease -- may be a first step towards a new era in the treatment of such disorders.